Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat with RDHAP in R/R DLBCL
NCT02532192Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of belinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 21 days. Planned start Dec 2015; status: withdrawn.
02
Drugs
belinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02532192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532192.